CSL profits, revenues up 10%, shares fall
There seems to be no pleasing demanding shareholders with biotechnology giant CSL punished by the market despite announcing a greater than ten per cent rise in both revenues and profits for the year to June 30. The Melbourne company reported net profit after tax of $3.27 billion (US$2.375 billion), up 10 per cent on a…